Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-CART-027 in Relapsed or Refractory Solid Tumors
NCT06951425Phase 1Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Jun 2025
- Primary completion
- Nov 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TH-CART-027 in osteosarcoma (OS), neuroblastoma, gastric cancer (GC) and 1 more, sponsored by Tongji Hospital. Primary endpoints: Incidence of Dose Limiting Toxicity at 28 days and Incidence and severity of adverse events at 6 months. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
TH-CART-027
03
Conditions
osteosarcoma (OS)neuroblastomagastric cancer (GC)lung cancer
Beyond the preview
Go deeper on NCT06951425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951425.